Search
(2S,3R,4S,5S)-3,4-Dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium
go.drugbank.com/drugs/DB03881ExperimentalSynonyms: (2S,3R,4S,5S)-3,4-Dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium6-methyl-formycin A
go.drugbank.com/drugs/DB03986ExperimentalSynonyms: 2-(7-amino-6-methyl-3H-pyrazolo[4,3-d]pyrimidin-3-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol, 6-methyl-formycin A4-Amino-1-[(1s,3r,4r,7s)-7-Hydroxy-1-(Hydroxymethyl)-2,5-Dioxabicyclo[2.2.1]Hept-3-Yl]-5-Methylpyrimidin-2(1h)-One
go.drugbank.com/drugs/DB03378ExperimentalSynonyms: 4-Amino-1-[(1s,3r,4r,7s)-7-Hydroxy-1-(Hydroxymethyl)-2,5-Dioxabicyclo[2.2.1]Hept-3-Yl]-5-Methylpyrimidin-2(1h)-OneAcid yellow 54 free acid
go.drugbank.com/drugs/DB03442ExperimentalSynonyms: 2-(5-hydroxy-3-methyl-1-(2-methyl-4-sulfophenyl)-1H-pyrazol-4-ylazo)-4-sulfobenzoic acid, Acid yellow 54 free acid(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
go.drugbank.com/drugs/DB07500ExperimentalSynonyms: (2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-oneN-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE
go.drugbank.com/drugs/DB07587ExperimentalSynonyms: N-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDESomapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666] … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersProducts: Sogroya® 10 mg/1.5 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet), Sogroya® 5 mg/1.5 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet)Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalIt is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. … In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsProducts: LEUSENOX 10 MG/10 ML IV INFÜZYON IÇIN KONSANTRE ÇÖZELTI IÇEREN AMPUL, 1 ADET, LEUSENOX 2 MG/ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 10 ADETSuvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein inhibitorsProducts: BELSOMRA® 20 MG, BELSOMRA® 10 MGPasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalPasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSynonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)